These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 35414604)

  • 21. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
    Subbarao S; Warrener LA; Hoschler K; Perry KR; Shute J; Whitaker H; O'Brien M; Baawuah F; Moss P; Parry H; Ladhani SN; Ramsay ME; Brown KE; Amirthalingam G
    Euro Surveill; 2021 Mar; 26(12):. PubMed ID: 33769252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.
    Pasikhova Y; Morrison AR; Katzman JH; Syed M
    Cancer Control; 2022; 29():10732748211070720. PubMed ID: 35001670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
    Liebers N; Speer C; Benning L; Bruch PM; Kraemer I; Meissner J; Schnitzler P; Kräusslich HG; Dreger P; Mueller-Tidow C; Poschke I; Dietrich S
    Blood; 2022 Jan; 139(1):142-147. PubMed ID: 34669919
    [No Abstract]   [Full Text] [Related]  

  • 24. Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
    Kozak KE; Ouyang L; Derkach A; Sherman A; McCall SJ; Famulare C; Chervin J; Daley RJ; Morjaria S; Mauro MJ; Rampal RK
    Leukemia; 2021 Dec; 35(12):3578-3580. PubMed ID: 34741117
    [No Abstract]   [Full Text] [Related]  

  • 25. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
    Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
    Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
    Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
    Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
    Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
    [No Abstract]   [Full Text] [Related]  

  • 29. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
    Connolly CM; Boyarsky BJ; Ruddy JA; Werbel WA; Christopher-Stine L; Garonzik-Wang JM; Segev DL; Paik JJ
    Ann Intern Med; 2021 Sep; 174(9):1332-1334. PubMed ID: 34029488
    [No Abstract]   [Full Text] [Related]  

  • 30. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
    Golding B; Lee Y; Golding H; Khurana S
    Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
    [No Abstract]   [Full Text] [Related]  

  • 32. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
    Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
    J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
    [No Abstract]   [Full Text] [Related]  

  • 33. Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.
    Mack PC; Hirsch FR; Bunn PA; Minna JD
    J Clin Oncol; 2022 Nov; 40(33):3787-3789. PubMed ID: 35759731
    [No Abstract]   [Full Text] [Related]  

  • 34. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
    Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
    Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
    [No Abstract]   [Full Text] [Related]  

  • 36. Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination.
    Cao J; Liu X; Muthukumar A; Gagan J; Jones P; Zu Y
    Clin Chem; 2021 Dec; 68(1):251-253. PubMed ID: 34358295
    [No Abstract]   [Full Text] [Related]  

  • 37. Side effects and antibody response of an inactive COVID-19 vaccine: correspondence.
    Mungmunpuntipantip R; Wiwanitkit V
    Rev Assoc Med Bras (1992); 2022 Apr; 68(4):443. PubMed ID: 35649063
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
    Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
    BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
    Baron F; Canti L; Ariën KK; Kemlin D; Desombere I; Gerbaux M; Pannus P; Beguin Y; Marchant A; Humblet-Baron S
    Front Immunol; 2022; 13():827242. PubMed ID: 35309332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.
    Caillard S; Thaunat O; Benotmane I; Masset C; Blancho G
    Ann Intern Med; 2022 Mar; 175(3):455-456. PubMed ID: 35007148
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.